ClinicalTrials.gg
RecruitingNCT07621783LEADERUpdated Jun 2, 2026

Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context

An observational study in Crohn Disease (CD) and Ulcerative Colitis (UC), sponsored by Imelda GI Clinical Research Center. Recruiting at 1 site in Belgium. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Imelda GI Clinical Research Center · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
100
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 194 studies in Crohn Disease with a site in Belgium — 41 open to participants now, 56 under way, 29 of them phase 3. Crohn Disease · Belgium.

Planned enrollment
14th of 19
100 · median 257
Started
2026
with 5 others
Observational
19 of 194
4 open now
Primary completion
2026-12
later than 14 of 55 live
Registered
194th of 194
by date

Among the 194 studies in Crohn Disease with a site in Belgium, this one is the 14th largest by planned enrollment of the 19 observational ones that give a count, is one of 6 that started in 2026, is one of 19 observational ones, reaches primary completion later than 14 of the 55 other live ones, and was the 194th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

41 of the 194 studies in Crohn Disease with a site in Belgium are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Crohn Disease with a site in Belgium, or all of them as a file.
02

Study summary

Prospectively study the correlation between Leucine-rich α2-glycoprotein (LRG) and clinical/endoscopic/histological disease activity in patients with inflammatory bowel disease (IBD) in Europe.

03

Conditions studied

  • Crohn Disease (CD)
  • Ulcerative Colitis (UC)

Keywords

  • Crohn; ulcerative colitis, LRG, endoscopic remission, endoscopic activity, PRO, quality of life
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients with IBD

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years
  2. Patient with confirmed diagnosis of IBD
  3. Patient with planned endoscopy (ileocolonoscopy for Crohn's disease (CD)/ulcerative colitis (UC) or sigmoidoscopy for UC) for the assessment of endoscopic disease activity according to routine practice
  4. willing to provide

Exclusion criteria

Exclusion Criteria:

  1. Patient with IBD unspecified
  2. Patient with ileo- or colostomy
  3. Patient with total colectomy
  4. Women that are pregnant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • patient with IBD

    patient with Crohn or ulcerative colitis

    Diagnostic Test: Leucine-rich α2-glycoprotein

Interventions

  • Diagnostic testLeucine-rich α2-glycoprotein

    Leucine-rich α2-glycoprotein measurement

06

What researchers measure

Primary outcomes

  1. Correlation between LRG serum level and endoscopic disease activity in CD and UC

    Correlation between LRG serum level and endoscopic disease activity in CD and UC

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2026
First posted
Jun 2, 2026
StartActual
May 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07621783
Lead sponsor
Imelda GI Clinical Research Center
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
May 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 2, 2026

Study contacts

Peter Bossuyt
Contact
peter.bossuyt@imelda.be
MD PhD

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion